The limits of evidence in drug approval and availability: A case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication

Clinical Therapeutics

Volumn 36, Issue 8, 2014, Pages 1290-1301

  Hong, Haeyeon ^a   Mackey, William C ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cilostazol; naftidrofuryl; pharmacotherapy for intermittent claudication; Pletal; Praxilene; treatment for intermittent claudication

Indexed keywords

CILOSTAZOL; CYCLIC AMP; NAFTIDROFURYL; NAFTIDROFURYL OXALATE; PENTOXIFYLLINE; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

ARTICLE; BLEEDING TIME; CHEMICAL STRUCTURE; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DRUG APPROVAL; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; GOLD STANDARD; HUMAN; INTERMITTENT CLAUDICATION; MEDLINE; QUALITY CONTROL; SOCIAL INTERACTION; STANDARDIZATION; THROMBOCYTE AGGREGATION; UNITED KINGDOM; UNITED STATES; URINARY EXCRETION; VASCULAR SMOOTH MUSCLE; WALKING SPEED; BIOASSAY; CLINICAL TRIAL (TOPIC); GREAT BRITAIN; METHODOLOGY; STANDARDS;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; ENDPOINT DETERMINATION; GREAT BRITAIN; HUMANS; INTERMITTENT CLAUDICATION; NAFRONYL; RESEARCH DESIGN; TETRAZOLES; UNITED STATES; VASODILATOR AGENTS;

EID: 84911976460     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.06.010     Document Type: Review

References (52)

1. L. Norgren, W.R. Hiatt, and J.A. Dormandy et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg 33 Suppl 1 2007 S1 75
2. M.M. McDermott, P. Greenland, and J.M. Guralnik et al. Depressive symptoms and lower extremity functioning in men and women with peripheral arterial disease J Gen Intern Med 18 2003 461 467
3. M.H. Criqui, A. Fronek, E. Barrett-Connor, M.R. Klauber, S. Gabriel, and D. Goodman The prevalence of peripheral arterial disease in a defined population Circulation 71 1985 510 515
4. J. Margolis, J.J. Barron, and W.D. Grochulski Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data J Manag Care Pharm JMCP 11 2005 727 734
5. W.R. Hiatt The US experience with cilostazol in treating intermittent claudication Atheroscler Suppl 6 2005 21 31
6. D.L. Dawson, B.S. Cutler, and W.R. Hiatt et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication Am J Med 109 2000 523 530
7. D. Moher, B. Pham, M. Ausejo, A. Saenz, S. Hood, and G.G. Barber Pharmacological management of intermittent claudication: a meta-analysis of randomised trials Drugs 59 2000 1057 1070
8. T.L.M. De Backer, R. Vander Stichele, P. Lehert, and L. Van Bortel Naftidrofuryl for intermittent claudication Cochrane Database Syst Rev 12 2012 CD001368
9. B. Girolami, E. Bernardi, and M.H. Prins et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis Arch Intern Med 159 1999 337 345
10. NICE Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease 2011 National Institute for Health and Clinical Excellence London
11. C. Tilstone Cilostazol (Pletal): risks of cardiovascular and bleeding events - indication restricted to second-line treatment and contraindicated with some cardiovascular conditions and medicines Drug Saf Update 6 2013
12. J.W. Stevens, E. Simpson, and S. Harnan et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication Br J Surg 99 2012 1630 1638
13. J. Shalhoub, and A.H. Davies Adjunctive pharmacotherapies for intermittent claudication - NICE guidance Heart Br Card Soc 98 2012 244 245
14. T. Nishi, K. Yamamoto, T. Shimizu, T. Kanbe, Y. Kimura, and K. Nakagawa Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. I. Alkyl 4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyrates and related compounds Chem Pharm Bull (Tokyo) 31 1983 798 810
15. Y. Liu, Y. Shakur, and J. Kambayashi Phosphodiesterases as targets for intermittent claudication S.H. Francis, M. Conti, M.D. Houslay, Phosphodiesterases as drug targets Vol 204 2011 Springer Berlin Heidelberg Berlin, Heidelberg 211 236 http://www.springerlink.com/index/10.1007/978-3-642- 17969-3-9. Accessed December 9, 2013
16. Y. Liu, M. Fong, J. Cone, S. Wang, M. Yoshitake, and J. Kambayashi Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication J Cardiovasc Pharmacol 36 2000 351 360
17. K. Schrör The pharmacology of cilostazol Diabetes Obes Metab 4 Suppl 2 2002 S14 S19
18. D.H. Maurice Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system Mol Pharmacol 64 2003 533 546
19. T. Nakamura, H. Houchi, and A. Minami et al. Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta Life Sci 69 2001 1709 1715
20. Y. Nishio, A. Kashiwagi, and N. Takahara et al. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells Horm Metab Res Horm- Stoffwechselforschung Horm Métabolisme 29 1997 491 495
21. S.L. Bramer, W.P. Forbes, and S. Mallikaarjun Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease Clin Pharmacokinet 37 Suppl 2 1999 1 11
22. D.R. Goldsmith, and K. Wellington Naftidrofuryl: a review of its use in the treatment of intermittent claudication Drugs Aging 22 2005 967 977
23. S.M. Sabry, T.S. Belal, M.H. Barary, and M.E.A. Ibrahim Spectrophotometric, spectrofluorimetric and voltammetric analyses of naftidrofuryl oxalate in its tablets Int J Biomed Sci IJBS 5 2009 283 292
24. N.F. Wiernsperger Serotonin, 5-HT2 receptors, and their blockade by naftidrofuryl: a targeted therapy of vascular diseases J Cardiovasc Pharmacol 23 Suppl 3 1994 S37 S43
25. N.K. Hollenberg, and Q. Nie The effect of naftidrofuryl, a 5-HT2 antagonist, on collateral vascular responses to serotonin and to platelet activation J Cardiovasc Pharmacol 16 Suppl 3 1990 S36 S39
26. F. De Clerck The role of serotonin in thrombogenesis Clin Physiol Biochem 8 Suppl 3 1990 40 49
27. T.N. Zaidi, L.V. McIntire, D.H. Farrell, and P. Thiagarajan Adhesion of platelets to surface-bound fibrinogen under flow Blood 88 1996 2967 2972
28. C. Le Dévéhat, T. Khodabandehlou, and M. Mosnier Effect of naftidrofuryl on platelet aggregation in plasma from aspirin treated patients: an in vitro study Clin Hemorheol Microcirc 22 2000 197 204
29. P. Bodin, and P. Travo Effects of naftidrofuryl on the contraction and proliferation of cultured myocytes evoked by serotonin J Cardiovasc Pharmacol 16 Suppl 3 1990 S25 S28
30. T. Hulot, S. Gamand, T. Dupain, P. Ahtoy, and M. Bromet Influence of age on the pharmacokinetics of naftidrofuryl after single oral administration in elderly versus young healthy volunteers Arzneimittelforschung 48 1998 900 904
31. B.Q. Farah, J.P. Souza Barbosa, A. dos, and G.G. Cucato et al. Predictors of walking capacity in peripheral arterial disease patients Clin São Paulo Braz 68 2013 537 541
32. A.W. Gardner, J.S. Skinner, B.W. Cantwell, and L.K. Smith Progressive vs single-stage treadmill tests for evaluation of claudication Med Sci Sports Exerc 23 1991 402 408
33. P.P. Dobesh, Z.A. Stacy, and E.L. Persson Pharmacologic therapy for intermittent claudication Pharmacotherapy 29 2009 526 553
34. M.M. McDermott, K. Liu, J.M. Guralnik, G.J. Martin, M.H. Criqui, and P. Greenland Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease J Vasc Surg 28 1998 1072 1081
35. J. Regensteiner, J. Steiner, R. Panzer, and W. Hiatt Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease J Vasc Med Biol 2 1990 142 152
36. J. Ware, K. Snow, M. Kosinski, and B. Gandet SF-36 health survey: manual and interpretation guide 1993 The Health Institute, New England Medical Centre Boston
37. S.A. Scherer, W.R. Hiatt, and J.G. Regensteiner Lack of relationship between gait parameters and physical function in peripheral arterial disease J Vasc Surg 44 2006 782 788
38. J.A. Dormandy, and R.B. Rutherford Management of peripheral arterial disease (PAD) J Vasc Surg 31 2000 S1 S296
39. Outcome assessment of intermittent claudication in clinical practice. J Vasc Surg. 2000;31:S74-S77.
40. T.E. Rowlands, and R. Donnelly Medical therapy for intermittent claudication Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg 34 2007 314 321
41. Center for Drug Evaluation and Research. New Drug Application for Pletal (cilostazol) Tablet. 1999. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/99/20863.cfm. Accessed May 15, 2013.
42. P.D. Thompson, R. Zimet, W.P. Forbes, and P. Zhang Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication Am J Cardiol 90 2002 1314 1319
43. D. Jacoby, and E.R. Mohler 3rd Drug treatment of intermittent claudication Drugs 64 2004 1657 1670
44. A.H. Davies, and C.M. Brophy Vascular surgery 2006 Springer London http://site.ebrary.com/id/10228787. Accessed December 22, 2013
45. Otsuka Pharmaceuticals. Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease comments on the ACD and evaluation report submitted to the national institute for health and clinical excellence (NICE) by Otsuka Pharmaceuticals. 2011. Available at: http://www.nice.org.uk/nicemedia/live/12265/54079/54079.pdf. Accessed June 1, 2013.
46. Rodin S. Cilostazol (NDA 20-863, Otsuka America): Overview and commentary on the efficacy and safety evidence. 1998. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/nda/99/20863-medr-P16.pdf. Accessed May 18, 2013.
47. The Sage Group Reports that in 2007 Between 4 and 8.4 Million Europeans Suffered from the Symptoms of Intermittent Claudication. Business Wire. http://www.businesswire.com/news/home/20080228006015/en/SAGE-GROUP-Reports-2007- 4-8.4-Million. Published February 28, 2008. Accessed November 15, 2013.
48. M. Dickson, and J.P. Gagnon Key factors in the rising cost of new drug discovery and development Nat Rev Drug Discov 3 2004 417 429
49. A.S. Kesselheim Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation N Engl J Med 363 2010 1855 1862
50. Product Report: Praxilene. Retrieved from Evaluate Ltd. database. Accessed Nov 1, 2013
51. A.J.J. Wood A proposal for radical changes in the drug-approval process N Engl J Med 355 2006 618 623
52. Collard A. Product report: Cilostazol. Evaluate Ltd; London, UK: 2013.